{
  "ticker": "NUZ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974288",
  "id": "02974288",
  "pages": 13,
  "price_sensitive": true,
  "date": "20250730",
  "time": "0914",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250730/pdf/06m9bqkx3f8t0l.pdf",
  "summary": "### **Neurizon Therapeutics Limited \u2013 Q4 FY25 Quarterly Report (Appendix 4C) \u2013 Material Information Summary**  \n\n#### **Key Operational/Financial Highlights:**  \n- **Clinical Progress:**  \n  - Successful completion of the 12-month **Open Label Extension (OLE) Study** for NUZ-001 in ALS, showing:  \n    - **78.5% reduction in risk of death** (hazard ratio: 0.215, p=0.0015).  \n    - Median **survival extension of \u226511 months** vs. historical controls.  \n    - No serious adverse events reported; results due Q3 CY2025.  \n  - **FDA Clinical Hold Update:** Submission of **Clinical Hold Complete Response (CHCR)** on 24 July 2025; FDA decision expected in 30 days.  \n\n- **Preclinical Advances:**  \n  - NUZ-001 demonstrated **neuroprotective effects** in Huntington\u2019s disease (BDNF restoration) and ALS (TDP-43 aggregation reduction).  \n  - Mechanistic studies suggest **potential beyond autophagy modulation**.  \n\n- **Regulatory & Partnerships:**  \n  - **Exclusive global license agreement with Elanco Animal Health** for monepantel (NUZ-001 API), including:  \n    - **Up to $9.75M** in development milestones + **$65M sales milestones** + royalties.  \n    - Access to Elanco\u2019s safety/manufacturing data to accelerate regulatory approvals.  \n  - **$1.5M R&D tax rebate-backed loan** secured post-quarter (17% interest).  \n\n- **Cash Position:**  \n  - **Closing cash balance: $4.2M** (30 June 2025).  \n  - **Net operating cash outflow: $4.4M** (20% reduction QoQ).  \n  - Estimated funding runway: **0.9 quarters** (without additional financing).  \n\n#### **Upcoming Catalysts:**  \n- **Q1 FY2026:** OLE study results, FDA hold resolution, HEALEY ALS Trial protocol submission.  \n- **Q2 FY2026:** HEALEY Trial initiation, Fast Track designation request.  \n\n---  \n**Omitted:** Routine community engagements, non-material preclinical details, director appointments.  \n**Concern:** Limited cash runway (~3 months) pending further funding.",
  "usage": {
    "prompt_tokens": 9123,
    "completion_tokens": 492,
    "total_tokens": 9615,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-29T23:27:40.800347"
}